Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONCOS-102 plus Balstilimab in PD-1 Resistant Melanoma
NCT05561491Phase 2Withdrawn
- Sponsor
- Targovax
- Start
- Jan 2024
- Primary completion
- Jun 2027
- Modality
- Oncolytic Viruses, Vaccines & Immunotherapeutics
01
Overview
A Phase 2 trial of ONCOS-102 in cutaneous melanoma (CM), sponsored by Targovax. Planned start Jan 2024; status: withdrawn.
02
Drugs
ONCOS-102
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT05561491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05561491.